NIBE Regulatory Approval

NIBE Credit Rating

Infomerics assigned fresh credit ratings to NIBE's bank facilities: IVR BBB-/Stable long-term and IVR A3 short-term. The ratings cover total bank loan facilities of Rs.180 Crore.

NIBE Management Change

Nibe Limited announced the resignation of Mrs. Ranjana Manoj Mimani as a Non-Executive, Non-Independent Director, effective September 29, 2026.

NIBE Annual General Meeting

Nibe Limited conducted its 21st Annual General Meeting on September 29, 2026. Shareholders discussed and approved various business items, including dividend declaration and related party transactions.

NIBE Partnership

NIBE Limited signed an MoU with Naval Group, France, to cooperate on naval technologies, strengthening India's self-reliance in shipbuilding and maritime defense.

From

Naval Group, France

NIBE Other Announcement

Nibe Ltd dispatched letters to shareholders with unregistered email addresses, providing access to the Annual Report for FY 2025-26 and reminding them to update KYC details.

NIBE Annual Report

Nibe Limited has submitted its 21st Annual Report for the financial year 2025-26. The report includes the notice for the Annual General Meeting.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.